{
    "2019-12-08": [
        [
            {
                "time": "2019-12-05",
                "original_text": "【国盛医药张金洋团队】周观点：智飞生物研发管线有望获得市场重估，“销售+研发”双轮驱动",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "研发管线",
                        "市场重估",
                        "销售+研发",
                        "双轮驱动"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-05",
                "original_text": "几项政策的浅析与投资节奏的把握 -- 医药行业周报（2019.12.02-2019.12.08）",
                "features": {
                    "keywords": [
                        "政策浅析",
                        "投资节奏",
                        "医药行业"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}